By Targeted News Service
ALEXANDRIA, Va., July 25 -- Bristol-Myers Squibb, Princeton, New Jersey, has been assigned a patent (8,785,398) developed by four co-inventors for the "methods of treatment using CTLA4 mutant molecules." The co-inventors are Robert James Peach, San Diego, Joseph Naemura, Bellevue, Washington, Peter S. Linsley, Seattle, and Jurgen Bajorath, Bonn, Germany.
The patent application was filed on Oct. 20, 2011 (13/277,425). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=87,85,398.PN.&OS=PN/87,85,398&RS=PN/87,85,398
Written by Sudarshan Harpal; edited by Jaya Anand.
(c) 2014 Targeted News Service